Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Shares Issued (2021 - 2025)

Kiniksa Pharmaceuticals International's Shares Issued history spans 5 years, with the latest figure at $8.6 million for Q4 2025.

  • For Q4 2025, Shares Issued rose 215.29% year-over-year to $8.6 million; the TTM value through Dec 2025 reached $40.8 million, up 136.25%, while the annual FY2025 figure was $40.8 million, 136.25% up from the prior year.
  • Shares Issued reached $8.6 million in Q4 2025 per KNSA's latest filing, down from $16.3 million in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $16.3 million in Q3 2025 to a low of $510000.0 in Q1 2023.
  • Average Shares Issued over 5 years is $3.6 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Shares Issued: plummeted 78.77% in 2022, then skyrocketed 1022.91% in 2025.
  • A 5-year view of Shares Issued shows it stood at $1.2 million in 2021, then rose by 6.44% to $1.3 million in 2022, then decreased by 25.81% to $957000.0 in 2023, then skyrocketed by 184.22% to $2.7 million in 2024, then skyrocketed by 215.29% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Shares Issued are $8.6 million (Q4 2025), $16.3 million (Q3 2025), and $12.7 million (Q2 2025).